DNA vaccines: A review

Journal of Internal Medicine

Volumn 253, Issue 4, 2003, Pages 402-410

  Liu, Margaret A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Clinical efficacy; CTL (cytotoxic T lymphocyte); DNA vaccines; Genes; Infectious diseases

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEASLES VACCINE; MUMPS VACCINE; RUBELLA VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC DISEASE; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CANCER; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GENE FUNCTION; HUMAN; IMMUNOTHERAPY; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEASLES; MUMPS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEOMICS; REVIEW; RUBELLA; T LYMPHOCYTE ACTIVATION;

ANTIGENS; CLINICAL TRIALS; HUMANS; IMMUNE TOLERANCE; INFECTION CONTROL; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 0037388738     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01140.x     Document Type: Review

References (43)

1. Achievements in Public Health 1900-99. Impact of vaccines universally recommended for children. Morb Mortal Wkly Rep (MMWR) April 1999; 48: 243-8.
2. Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev 1987; 98: 95-114.
3. Johnson RP. Live attenuated AIDS vaccines: hazards and hopes [news; comment]. Nat Med 1999; 5: 154-5.
4. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
5. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
6. Ulmer JB, Deck RR, DeWitt CM, Donnelly JI, Liu MA. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996; 89: 59-67.
7. Corr M, von Damm A, Lee DJ, Tighe H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 1999; 163: 4721-7.
8. Fu TM, Ulmer JB, Caulfield MJ et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen-presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997; 3: 362-71.
9. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996; 184: 1555-60.
10. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann Rev Immunol 1997; 15: 617-48.
11. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Ann Rev Immunol 2000; 18: 927-74.
12. Srivastava IK, Liu MA. Gene vaccines. Ann Int Med 2003: 138: in press.
13. MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
14. Le TP, Coonan KM, Hedstrom RC et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18: 1893-901.
15. MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB. Safety and immune responses to a DNA-based human immunodeficiency virus (HW) type I env/rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis 2000; 181: 406.
16. Calarota SA, Leandersson AC, Bratt G et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol 1999; 163: 2330-8.
17. Roy MJ, Wu MS, Barr LJ et al. Induction of antigen-specific CD8+ T cells. T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19: 764-78.
18. Ugen KE, Nyland SB, Boyer JD et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998; 16: 1818-21.
19. Calarota SA, Kjerrstrom A, Islam KB, Wahren B. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum Gene Ther 2001; 12: 1623-37.
20. Wang R, Epstein J, Baraceros FM et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci 2001; 98: 10817-22.
21. Tang DC, De Vit M, Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-4.
22. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci 1993; 90: 11478-82.
23. Fuller JT, Fuller DH, McCabe D, Haynes JR, Widera G. Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization. Ann N Y Acad Sci 1995; 772: 282-4.
24. Swain WE, Heydenburg Fuller D, Wu MS et al. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B. Dev Biol 2000; 104: 115-9.
25. Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351: 1320-5.
26. Lundholm P, Leandersson AC, Christensson B, Bratt G, Sandstrom E, Wahren B. DNA mucosal HIV vaccine in humans. Virus Res 2002; 82: 141-5.
27. Lundholm P, Asakura Y, Hinkula J, Lucht E, Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 1999; 17: 2036-42.
28. Widera G, Austin M, Rabussay D et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-40.
29. Zucchelli S, Capone S, Fattori E et al. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 2000; 74: 11598-607.
30. O'Hagan D, Singh M, Ugozzoli M et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001; 75: 9037-43.
31. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-91.
32. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995; 270: 299-302.
33. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol 1999; 162: 1603-10.
34. Ulmer JB, DeWitt CM, Chastain M et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999; 18: 18-28.
35. Krieg AM. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol 1996; 4: 73-6.
36. Sato Y., Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-4.
37. Klinman D, Yamshchikov G, Ishigatsubo Y. Contribution of CpG Motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 3635-9.
38. Parker SE, Monteith D, Horton H et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 2001; 8: 1011-23.
39. Kim JJ, Yang J, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 2001; 19: 2496-505.
40. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998; 72: 10180-8.
41. Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1988; 4: 397-402.
42. Sedegah M, Weiss W, Sacci JB et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 2000; 164: 5905-12.
43. Johnston SA, Barry MA. Genetic to genomic vaccination. Vaccine 1997; 15: 808.